Blog
RSS FeedPosted by Michael Wonder on 24 Mar 2020
Quebec-based pharmaceutical company donates 1 million doses of malaria-drug for COVID-19 patients across Canada
23 March 2020 - Boucherville-based JAMP Pharma is donating one million doses of hydroxychloroquine to hospitals across Canada in the ...
Posted by Michael Wonder on 21 Mar 2020
Janssen announces Health Canada approval of Cabenuva, the first long-acting regimen for the treatment of HIV
20 March 2020 - Cabenuva offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression. ...
Posted by Michael Wonder on 10 Mar 2020
Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes
9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps. ...
Posted by Michael Wonder on 04 Mar 2020
Novartis receives Health Canada approval for Mayzent (siponimod) to treat secondary progressive multiple sclerosis with active disease
3 March 2020 - Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of people living ...
Posted by Michael Wonder on 03 Mar 2020
Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura
2 March 2020 - Cablivi is the first treatment approved in Canada for aTTP, a life-threatening blood clotting disorder. ...
Posted by Michael Wonder on 02 Mar 2020
'It's outrageous': costly cancer drugs thrown out because of one-size-fits-all packaging
1 March 2020 - Prescription drug negotiations steeped in secrecy, leaving taxpayers in the dark on costs. ...
Posted by Michael Wonder on 28 Feb 2020
Nuvo Pharmaceuticals announces Health Canada approves Suvexx for the acute treatment of migraine
27 February 2020 - Canadian launch anticipated in the second half of 2020. ...
Posted by Michael Wonder on 26 Feb 2020
Janssen receives Health Canada approval of Balversa (erdafitinib), the first FGFR kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations
24 February 2020 - Diagnostic testing is available to identify which patients are most likely to benefit from BALVERSA, offering a ...
Posted by Michael Wonder on 12 Feb 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis)
11 February 2020 - Eli Lilly Canada announced today that Health Canada approved Taltz (ixekizumab) on 4 February 2020, for the ...
Posted by Michael Wonder on 29 Jan 2020
Health Canada approves new indication for Invokana (canagliflozin) to reduce the risks associated with diabetic kidney disease in patients with type 2 diabetes
28 January 2020 - INVOKANA® is the only diabetes treatment in Canada approved to treat this patient group ...
Posted by Michael Wonder on 28 Jan 2020
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime
27 January 2020 - Jubilant Radiopharma announced today that the company received approval from Health Canada for Drax Exametazine (Kit ...
Posted by Michael Wonder on 28 Jan 2020
Health Canada approves new indication for Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis
27 January 2020 - In the Phase 3 pivotal trial, nearly 44% of patients receiving Stelara subcutaneous injections every 8 ...
Posted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
HLS Therapeutics files new drug submission for Perseris in Canada
23 January 2020 - If approved by Health Canada, Perseris would become the first once-monthly risperidone long-acting injectable used in the ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...